ep sale miss knee share
easi comp set stage miss knee unexpect sale
growth cc vs cse flat con almost enough
inorgan put take net minor posit
make adjust total sale growth sell day adjust
would actual make declin knee wors analysi
adjust includ unusu pattern sell day differ day
vs day vs loss bone cement
mil per quarter would affect adjust knee growth
declin knee similar time easier
comp vs suggest sequenti
deterior reiter under-perform rate target
lost anoth bp us knee share vs bp
estimate three four major ortho player report result
ww hip knee sale estim knee market grew
ww analysi ortho market
lost bp knee share gain bp
knee miss beat rel estim came hip
spine dental ep
estim penni consensu
valuat target price base ev/ebitda multipl
ebitda bil reflect expect share loss
declin organ growth put downward pressur valuat
increas ep estim beyond risk faster-
than-expect resolut suppli issu fda warn letter better-
than-expect uptak rosa
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
inc global manufactur provid
medic devic equip treatment
musculoskelet spinal disord trauma dental implant
one-year valuat scenario base
ev/ebitda ebitda
scenario base high-growth segment grow
growth grow
one-year valuat grey scenario base
ev/ebitda grey ebitda
grey scenario base high-growth segment grow
growth grow
 close
addit detail takeaway
knee mil mil y/i cc vs cse
america knee sale mil mil declin cc emea sale
mil mil cc apac sale mil mil increas
hip mil mil y/i cc vs cse
america hip sale mil mil decreas cc emea
sale mil mil cc apac sale mil mil
figur qtd ortho growth market share analysi actual estim
set sale mil mil y/i cc vs cse spine
cmf sale mil mil decreas y/i cc vs cse dental
revenu mil mil y/i cc vs cse
sale mil mil y/i cc vs cse
geograph america sale bil mil cc emea
sale mil in-lin increas cc apac sale mil mil
emea benefit top-lin rebat adjust quarter growth would
nearli exclud adjust
compani maintain sale growth guidanc fx
bp impli cc sale growth fx expect
impact expect heavili weight vs term
bill day day headwind spread evenli off-set
major benefit bottom-lin also maintain ep
guidanc
 oper margin in-lin estim
sale net cog higher non-op incom partial off-set higher
sg deliv beat ep rel estim gross
margin bp y/i bp estim
estimate bpop bpnon-op bpnet chg y/i charl martineau pm univers toronto
salesy/i chg cc cg salesy/i chg cc estimate varianc charl martineau pm univers toronto
chang model
top-lin leav estim rel unchang bottom-lin
increas ep estim beyond
figur chang model
target price base ebitda bil reflect
expect share loss declin organ growth put downward
pressur valuat risk rate faster-than-expect resolut suppli
issu faster-than-expect remedi fda warn letter better-than-
expect uptak rosa
compani mention price
matt miksic vik chopra certifi respect compani secur individu analyz view express
report accur reflect person view subject compani secur part compens
directli indirectli relat specif recommend view express report
